Anemoside B4 is primarily used in pharmaceutical research due to its anti-inflammatory and neuroprotective properties. It has shown potential in the development of treatments for ischemic stroke by helping to reduce brain injury and improve neurological function in preclinical models. The compound also exhibits protective effects on the intestinal mucosa, making it a candidate for managing inflammatory bowel diseases such as ulcerative colitis. Its ability to modulate signaling pathways involved in inflammation and apoptosis supports its investigation as a therapeutic agent in chronic inflammatory and neurodegenerative conditions. Additionally, Anemoside B4 is studied for its role in enhancing blood-brain barrier integrity, which may contribute to its efficacy in central nervous system disorders.